Security key
87164F105
Syndax Pharmaceuticals Inc - Common Stock, par value $0.0001 per share (SNDX)
CUSIP: 87164F105
Q4 2025 13F Holders as of 31 Dec 2025
- Type / Class
- Equity / Common Stock, par value $0.0001 per share
- Shares outstanding
- 86,328,130
- Total 13F shares
- 99,897,685
- Share change
- -2,696,391
- Total reported value
- $2,098,468,154
- Put/Call ratio
- 47%
- Price per share
- $21.01
- Number of holders
- 227
- Value change
- -$24,363,545
- Number of buys
- 110
- Number of sells
- 109
Report period
Q4 2025
Institutions
227
Top holders
10
SNDX full security history
Newer quarter: Q1 2026
Previous quarter: Q3 2025
Syndax Pharmaceuticals Inc SEC filings
Syndax Pharmaceuticals Inc company facts
Broader feeds
Reporting periods
Holder history for CUSIP 87164F105
Recent filing periods:
Top shareholders of SNDX - Syndax Pharmaceuticals Inc - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Kynam Capital Management, LP |
13F
13D/G
|
Company |
10%
from 13D/G
|
8,520,000
|
$131,080,200 | — | 30 Sep 2025 | |
| BlackRock, Inc. |
13F
13D/G
|
Company |
7.8%
from 13D/G
|
8,625,244
|
$132,699,393 | — | 30 Sep 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
13D/G
|
Company · THE GOLDMAN SACHS GROUP, INC. |
6.5%
from 13D/G
|
5,486,434
|
$84,408,787 | — | 30 Sep 2025 | |
| STATE STREET CORP |
13D/G
13F
|
STATE STREET CORPORATION · Company |
5.3%
|
4,596,552
|
$96,527,592 | $0 | 31 Dec 2025 | |
| MORGAN STANLEY |
13D/G
13F
|
Company |
2.4%
|
2,040,013
|
$27,193,373 | -$44,284,339 | 31 Mar 2025 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
13D/G
|
Company |
0.04%
from 13D/G
|
38,226
|
$588,107 | — | 30 Sep 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
6%
|
5,138,617
|
$79,057,621 | — | 30 Sep 2025 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
4.9%
|
4,255,047
|
$65,463,921 | — | 30 Sep 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
4.3%
|
3,697,753
|
$56,889,929 | — | 30 Sep 2025 | |
| Eversept Partners, LP |
13F
|
Company |
4%
|
3,467,314
|
$53,344,626 | — | 30 Sep 2025 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
|
Company |
3.8%
|
3,311,963
|
$50,954,551 | — | 30 Sep 2025 | |
| KINGDON CAPITAL MANAGEMENT, L.L.C. |
13F
|
Company |
2.9%
|
2,500,000
|
$38,462,500 | — | 30 Sep 2025 | |
| FRANKLIN RESOURCES INC |
13F
|
Company |
2.8%
|
2,390,561
|
$36,778,786 | — | 30 Sep 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
2.4%
|
2,091,331
|
$32,179,868 | — | 30 Sep 2025 | |
| Soleus Capital Management, L.P. |
13F
|
Company |
2.3%
|
2,012,110
|
$30,956,312 | — | 30 Sep 2025 | |
| Assenagon Asset Management S.A. |
13F
|
Company |
2.1%
|
1,784,139
|
$27,448,979 | — | 30 Sep 2025 | |
| UBS Group AG |
13F
|
Company |
1.9%
|
1,674,513
|
$25,762,382 | — | 30 Sep 2025 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
1.9%
|
1,644,844
|
$25,305,925 | — | 30 Sep 2025 | |
| Catalio Capital Management, LP |
13F
|
Company |
1.9%
|
1,614,717
|
$24,842,421 | — | 30 Sep 2025 | |
| Woodline Partners LP |
13F
|
Company |
1.8%
|
1,550,520
|
$23,854,750 | — | 30 Sep 2025 | |
| Nuveen, LLC |
13F
|
Company |
1.7%
|
1,475,798
|
$22,705,153 | — | 30 Sep 2025 | |
| MPM BioImpact LLC |
13F
|
Company |
1.6%
|
1,375,674
|
$21,164,744 | — | 30 Sep 2025 | |
| STEMPOINT CAPITAL LP |
13F
|
Company |
1.6%
|
1,366,205
|
$21,019,064 | — | 30 Sep 2025 | |
| Aisling Capital Management LP |
13F
|
Company |
1.5%
|
1,316,806
|
$20,265,644 | — | 30 Sep 2025 | |
| BNP Paribas Asset Management Holding S.A. |
13F
|
Company |
1.4%
|
1,236,077
|
$19,017,000 | — | 30 Sep 2025 | |
| D. E. Shaw & Co., Inc. |
13F
|
Company |
1.2%
|
1,077,585
|
$16,578,645 | — | 30 Sep 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
1.2%
|
1,052,335
|
$16,190,182 | — | 30 Sep 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
1.2%
|
1,046,456
|
$16,099,726 | — | 30 Sep 2025 | |
| Prosight Management, LP |
13F
|
Company |
1.2%
|
1,003,400
|
$15,437,309 | — | 30 Sep 2025 | |
| EVENTIDE ASSET MANAGEMENT, LLC |
13F
|
Company |
1.1%
|
988,486
|
$15,207,867 | — | 30 Sep 2025 | |
| ALGERT GLOBAL LLC |
13F
|
Company |
1.1%
|
930,766
|
$14,320,000 | — | 30 Sep 2025 | |
| S.c.a. Candriam |
13F
|
Individual |
1.1%
|
925,332
|
$14,236,233 | — | 30 Sep 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
1%
|
860,500
|
$13,238,793 | — | 30 Sep 2025 | |
| Parkman Healthcare Partners LLC |
13F
|
Company |
0.98%
|
846,899
|
$13,029,541 | — | 30 Sep 2025 | |
| Ensign Peak Advisors, Inc |
13F
|
Company |
0.94%
|
809,064
|
$12,447,450 | — | 30 Sep 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.9%
|
776,686
|
$11,949,314 | — | 30 Sep 2025 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.86%
|
738,266
|
$11,358,222 | — | 30 Sep 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.83%
|
719,034
|
$11,062,338 | — | 30 Sep 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.83%
|
712,659
|
$10,964,259 | — | 30 Sep 2025 | |
| Palo Alto Investors LP |
13F
|
Company |
0.76%
|
654,930
|
$10,076,098 | — | 30 Sep 2025 | |
| APIS CAPITAL ADVISORS, LLC |
13F
|
Company |
0.74%
|
638,000
|
$9,815,630 | — | 30 Sep 2025 | |
| BNP PARIBAS FINANCIAL MARKETS |
13F
|
Company |
0.69%
|
599,871
|
$9,229,015 | — | 30 Sep 2025 | |
| Rhenman & Partners Asset Management AB |
13F
|
Company |
0.66%
|
574,000
|
$8,830,990 | — | 30 Sep 2025 | |
| AQR CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.65%
|
558,076
|
$8,585,999 | — | 30 Sep 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.63%
|
546,268
|
$8,404,334 | — | 30 Sep 2025 | |
| DAFNA Capital Management LLC |
13F
|
Company |
0.58%
|
500,702
|
$7,703,300 | — | 30 Sep 2025 | |
| SILVERARC CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.54%
|
463,708
|
$7,134,148 | — | 30 Sep 2025 | |
| David M. Knott Jr. |
13F
|
Individual |
0.5%
|
428,000
|
$6,584,780 | — | 30 Sep 2025 | |
| Granahan Investment Management, LLC |
13F
|
Company |
0.46%
|
396,336
|
$6,097,630 | — | 30 Sep 2025 | |
| SPHERA FUNDS MANAGEMENT LTD. |
13F
|
Company |
0.45%
|
387,716
|
$5,965,011 | — | 30 Sep 2025 |
Institutional Holders of Syndax Pharmaceuticals Inc - Common Stock, par value $0.0001 per share (SNDX) as of Q4 2025
As of 31 Dec 2025,
Syndax Pharmaceuticals Inc - Common Stock, par value $0.0001 per share (SNDX) was held by
227 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
99,897,685 shares.
The largest 10 holders included
BlackRock, Inc., Kynam Capital Management, LP, VANGUARD GROUP INC, GOLDMAN SACHS GROUP INC, Point72 Asset Management, L.P., BANK OF AMERICA CORP /DE/, STATE STREET CORP, Eversept Partners, LP, FRANKLIN RESOURCES INC, and KINGDON CAPITAL MANAGEMENT, L.L.C..
This page lists
227
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
226
Q4 2025 holders
227
Holder diff
1
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 Value $ | Q4 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.